• Investing
  • Stock
  • Editor’s Pick
  • Economy
The Significant Deals
Stock

Mizuho refreshes its US top picks list for January

by January 8, 2025
written by January 8, 2025

Investing.com — Mizuho (NYSE:MFG) has updated its US Top Picks list for January, adding Chewy (NYSE:CHWY), GE Vernova (NYSE:GEV), Enliven Therapeutics Inc (NASDAQ:ELVN), Quest Diagnostics (NYSE:DGX), DuPont de Nemours (NYSE:DD), and Salesforce (NYSE:CRM). These selections reflect Mizuho’s highest-conviction ideas driven by catalysts expected to play out over the next 12 months.

Mizuho identifies Chewy as a top pick in the consumer internet space. According to the investment bank, the pet food retailer benefits from “multiple internal levers facilitating EBITDA margin expansion” and increasing engagement with its under-penetrated mobile app.

The firm also sees opportunities in the company’s vet-focused initiatives, adding that Chewy’s efforts to expand automation and build on secular category growth position it for sustained profitability.

“These factors combine for a still catalyst-rich name, self-funded through ample cash generation and with >$400M in remaining buybacks,” Mizuho analysts noted.

They set a price target of $42 for Chewy shares, implying more than 17% upside from the last closing price.

GE Vernova was also added to the US Top Picks list, thanks to its robust role in providing gas turbines, wind turbines, and grid equipment, supplying approximately 30% of the world’s electricity.

Mizuho estimates data center power demand will grow at a 21% compound annual growth rate (CAGR) through 2030 as a key growth driver. It expects “new natural gas power contracts to flow through in early 2025, followed by gas generator OEM orders in mid-2025.”

Other key catalysts that could emerge in the coming months include potential favorable regulatory and policy changes under Trump 2.0.

For Enliven Therapeutics, Mizuho analysts highlight the company’s investigational tyrosine kinase inhibitor (TKI) ​​ELVN-001 as showing promising early efficacy and safety data in previously treated patients. This strengthens its outlook alongside asciminib, which is expected to gain approval for front-line use in chronic myeloid leukemia (CML).

As asciminib expands in the front-line setting, the post-asciminib treatment landscape—where ELVN-001 is currently targeted—is likely to grow. Moreover, ELVN-001 could have potential in first-line treatment.

Quest Diagnostics was picked for its stable cash flow and growth potential in diagnostic services.

“We believe DGX has a clear line of sight into the company’s initial 2025 adjusted EPS guide of high-single digit (HSD) growth given the strength in its base diagnostics business, improved reimbursement backdrop, stable labor environment and upside potential from M&A,” analysts said.

Furthermore, the company benefits from a strong pricing environment across Medicare and commercial sectors, while maintaining a solid pipeline for outreach lab acquisitions, which is expected to be a priority in 2025.

Mizuho analysts see DuPont’s planned three-way split into ElectronicsCo, WaterCo, and the new DuPont as a value unlock, with ElectronicsCo and WaterCo aligning with high-multiple peers.

The new DuPont is expected retain leadership in nonwoven fabrics and specialty materials under brands like Kevlar and Tyvek. Mizuho’s $100 valuation reflects a conservative discount, factoring in the 18-24 month timeline and the unseasoned nature of the new entities.

Key catalysts include seasonal sales improvements, electronics recovery, and progress toward the split.

Salesforce rounds out the January additions to the US Top Picks list. Analysts view Salesforce as well-positioned to drive digital transformation for its large customer base, leveraging its core role in sales, marketing, and customer support.

The company’s Data Cloud and Agentforce technology are seen as key drivers of productivity and revenue growth.

“Agentforce has the potential to be game-changing technology by driving material productivity improvements and a strong ROI, thus unlocking major benefits for customers while driving bookings and revenue re-acceleration for CRM, analysts emphasized.

They also highlight Salesforce’s focus on profitable growth, with catalysts including Agentforce 2.0 updates, large multi-cloud deals, operating margin performance, and the appointment of a new CFO.

This post appeared first on investing.com
0 comment
0
FacebookTwitterPinterestEmail

previous post
Lufthansa to acquire 41% stake in ITA for EUR 325 million
next post
AMD invests $20 million in Absci to expand AI chip sales in healthcare sector- WSJ

You may also like

BASF results down on impairments, restructuring

January 27, 2025

European chipmakers slump as traders gauge DeepSeek AI...

January 27, 2025

Nasdaq futures tumble as China’s AI push rattles...

January 27, 2025

China Vanke’s CEO, chairman resign amid growing liquidity...

January 27, 2025

Fuji Media, rocked by sexual misconduct allegations, says...

January 27, 2025

Italy’s MPS shares fall ahead of Mediobanca board...

January 27, 2025

British Land stock drops following stake sale

January 27, 2025

UMG shares rally after new multi-year pact with...

January 27, 2025

BASF shares indicated 3% lower as impairments drag...

January 27, 2025

Ryanair cuts 2026 traffic forecast amid ongoing Boeing...

January 27, 2025
Fill Out & Get More Relevant News








    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Recent Posts

    • Divided Fed proposes rule to ease capital requirements for big Wall Street banks

      June 26, 2025
    • Women’s Tennis Association extends media rights deal with Tennis Channel through 2032

      June 26, 2025
    • Bumble shares jump 26% as dating company plans to axe 30% of workforce

      June 26, 2025
    • Small-business AI use is lagging, but one firm is channeling Sherlock Holmes and knocking out ‘grunt work’

      June 25, 2025

    Categories

    • Economy (245)
    • Editor's Pick (3,646)
    • Investing (534)
    • Stock (6,426)

    Latest News

    • Divided Fed proposes rule to ease capital requirements for big Wall Street banks
    • Women’s Tennis Association extends media rights deal with Tennis Channel through 2032

    Popular News

    • Analysis-For Europe’s markets, Trump’s return spells euro pain but bond gains
    • Google proposes fresh tweaks to search results in Europe

    About The Significant deals

    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 thesignificantdeals.com | All Rights Reserved

    The Significant Deals
    • Investing
    • Stock
    • Editor’s Pick
    • Economy